CG Oncology Inc

CGON remains in a healthy longer-term uptrend but is currently consolidating around the 50-day SMA after pulling back below the 9- and 20-day EMAs. Short-term timing is unfavorable while price trades under its short EMAs, so execution should be deferred until we see clear acceptance and a tighter trading range at this support zone. Medium-term bias stays bullish based on the Stage 2 advancing structure, but patience is warranted to avoid chasing into extended weakness.

• ↑75% complete response rate in NMIBC trial signals clinical edge
• ↑FY26 consensus revenue estimates up 35% to $4.47M
• ↓Q2 2026 net loss $79.1M and R&D expenses of $54.7M